索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]刘权仪 吴新华 陈章荣.雌激素对血管、心肌保护性作用的分子机制[J].国际心血管病杂志,2018,04:204-207.
点击复制

雌激素对血管、心肌保护性作用的分子机制(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2018年04期
页码:
204-207
栏目:
综述
出版日期:
2018-07-25

文章信息/Info

Title:
-
作者:
刘权仪 吴新华 陈章荣
Author(s):
-
关键词:
雌激素;  血管保护;  分子机制;  血管钙化
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2018.04.004
文献标识码:
-
摘要:
雌激素具有调节血管功能、保护内皮、抗动脉粥样硬化、抑制血管钙化、调节心肌电活动和抑制心肌细胞凋亡等作用,在预防心血管疾病方面具有重要的临床价值。雌激素可产生复杂的生物学效应,其保护作用机制涉及较多的信号通路,如丝裂原活化蛋白激酶途径、磷脂酰肌醇-3激酶/蛋白激酶B途径和骨保护素/核因子κB受体活化因子配体途径等。该文主要介绍雌激素对血管内皮、血管平滑肌和心肌的保护性作用的分子机制
Abstract:
-

参考文献/References


[1] Reckelhoff JF, Maric C. Sex and gender differences in cardiovascular-renal physiology and pathophysiology[J]. Steroids, 2010, 75(11):745-746.
[2] Rosano G, Vitale C, Marazzi G, et al. Menopause and cardiovascular disease: the evidence[J]. Climacteric, 2007, 10(1):19-24.
[3] Wake R, Yoshiyama M. Gender differences in ischemic heart disease[J]. Recent Pat Cardiovasc Drug Discov, 2009, 4(3):234-240.
[4] Kim ES, Menon V. Status of women in cardiovascular clinical trials[J]. Arterioscler Thromb Vasc Biol, 2009, 29(3):279-283.
[5] Anderson RD, Pepine CJ. Gender differences in the treatment for acute myocardial infarction: bias or biology?[J]. Circulation, 2007, 115(7):823-826.
[6] Mendelsohn ME. Protective effects of estrogen on the cardiovascular system[J]. Am J Cardiol, 2002, 89(12A):12E-18E.
[7] Prossnitz ER, Maggiolini M. Mechanisms of estrogen signaling and gene expression via GPR30[J]. Mol Cell Endocrinol, 2009, 308(1/2):32-38.
[8] Tostes RC, Nigro D, Fortes ZB, et al. Effects of estrogen on the vascular system[J]. Braz J Med Biol Res, 2003, 36(9):1143-1158.
[9] Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences[J]. Science, 2005, 308(5728):1583-1587.
[10] Scott PA, Tremblay A, Brochu M, et al. Vasorelaxant action of 17-estradiol in rat uterine arteries: role of nitric oxide synthases and estrogen receptors[J]. Am J Physiol Heart Circ Physiol, 2007, 293(6):H3713-H3719.
[11] Rosenfeld CR, White RE, Roy T, et al. Calcium-activated potassium channels and nitric oxide coregulate estrogen-induced vasodilation[J]. Am J Physiol Heart Circ Physiol, 2000, 279(1):H319-H328.
[12] Florian M, Lu Y, Angle M, et al. Estrogen induced changes in Akt-dependent activation of endothelial nitric oxide synthase and vasodilation[J]. Steroids, 2004, 69(10):637-645.
[13] Losordo DW, Isner JM. Estrogen and angiogenesis[J]. Arterioscler Thromb Vasc Biol, 2001, 21(1):6-12.
[14] Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function[J]. Cardiovasc Res, 2002, 53(3):605-619.
[15] 王宇, 杨欣, 李晓冬, 等. 雌激素抑制内质网应激引起的血管内皮细胞凋亡及机制[J]. 中国动脉硬化杂志, 2016, 24(3):217-223.
[16] Ueda K, Karas RH. Emerging evidence of the importance of rapid, non-nuclear estrogen receptor signaling in the cardiovascular system[J]. Steroids, 2013, 78(6):589-596.
[17] Trenti A, Tedesco S, Boscaro C, et al. Estrogen, angiogenesis, immunity and cell metabolism: solving the puzzle[J]. Int J Mol Sci, 2018, 19(3):E859.
[18] Mautner GC, Mautner SL, Froehlich J, et al. Coronary artery calcification: assessment with electron beam CT and histomorphometric correlation[J]. Radiology, 1994, 192(3):619-623.
[19] Budoff MJ, Achenbach S, Blumenthal RS, et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology[J]. Circulation, 2006, 114(16):1761-1791.
[20] Arad Y, Spadaro LA, Goodman K, et al. Prediction of coronary events with electron beam computed tomography[J]. J Am Coll Cardiol, 2000, 36(4):1253-1260.
[21] Raggi P, Shaw LJ, Berman DS, et al. Prognostic value of coronary artery calcium screening in subjects with and without diabetes[J]. J Am Coll Cardiol, 2004, 43(9):1663-1669.
[22] Greenland P, Labree L, Azen SP, et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals[J]. JAMA, 2004, 291(2):210-215.
[23] Wu M, Rementer C, Giachelli CM. Vascular calcification: an update on mechanisms and challenges in treatment[J]. Calcif Tissue Int, 2013, 93(4):365-373.
[24] Osako MK, Nakagami H, Koibuchi N, et al. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification[J]. Circ Res, 2010, 107(4):466-475.
[25] Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification[J]. N Engl J Med, 2007, 356(25):2591-2602.
[26] 孙文学, 刘毅, 阮吉, 等. 雌激素对大鼠血管钙化消退的影响[J]. 中华肾脏病杂志, 2012, 28(11):879-882.
[27] Nanao-Hamai M, Son BK, Hashizume T, et al. Protective effects of estrogen against vascular calcification via estrogen receptor α-dependent growth arrest-specific gene 6 transactivation[J]. Biochem Biophys Res Commun, 2016, 480(3):429-435.
[28] Grohé C, Kahlert S, Löbbert K, et al. Cardiac myocytes and fibroblasts contain functional estrogen receptors[J]. FEBS Lett, 1997, 416(1):107-112.
[29] Stice JP, Chen L, Kim SC, et al. 17β-Estradiol, aging, inflammation, and the stress response in the female heart[J]. Endocrinology, 2011, 152(4):1589-1598.
[30] Wang XT, Nagaba S, Nagaba Y, et al. Cardiac L-type calcium channel alpha 1-subunit is increased by cyclic adenosine monophosphate: messenger RNA and protein expression in intact bone[J]. J Bone Miner Res, 2000, 15(7):1275-1285.
[31] Donaldson C, Eder S, Baker C, et al. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation[J]. Circ Res, 2009, 104(2):265-275.
[32] Patten RD, Pourati I, Aronovitz MJ, et al. 17beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling[J]. Circ Res, 2004, 95(7):692-699.
[33] Gardner JD, Murray DB, Voloshenyuk TG, et al. Estrogen attenuates chronic volume overload induced structural and functional remodeling in male rat hearts[J]. Am J Physiol Heart Circ Physiol, 2010, 298(2):H497-H504.
[34] Menazza S, Sun J, Appachi S, et al. Non-nuclear estrogen receptor alpha activation in endothelium reduces cardiac ischemia-reperfusion injury in mice[J]. J Mol Cell Cardiol, 2017, 107:41-51.
[35] Duft K, Schanz M, Pham H, et al. 17β-Estradiol-induced interaction of estrogen receptor α and human atrial essential myosin light chain modulates cardiac contractile function[J]. Basic Res Cardiol, 2017, 112(1):1.
[36] Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women having undergone hysterectomy: the Women's Health Initiative randomized, controlled trials[J]. Obstet Gynecol, 2004, 59(8):599-600.
[37] Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative[J]. Arch Intern Med, 2006, 166(3):357-365.
[38] Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause[J]. JAMA, 2007, 297(13):1465-1477.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81560073)
作者单位:671000 大理大学第一附属医院心内科
通信作者:吴新华,Email: 13987286915@139.com
更新日期/Last Update: 2018-07-30